What patients should be told before agreeing to a blood test that could change their lives

Urology

Volumn 61, Issue 1, 2003, Pages 7-9

  Talcott, James A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRIA; BIOPSY; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; DECISION MAKING; EDITORIAL; EMOTION; EUROPE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MEDICAL EXAMINATION; MELANOMA; METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES;

HEALTH CARE AND PUBLIC HEALTH; PROFESSIONAL PATIENT RELATIONSHIP;

DECISION MAKING; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PHYSICIAN'S ROLE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0037259126     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02148-9     Document Type: Editorial

References (25)

1. Tannock I.F. Eradication of a disease how we cured symptomless prostate cancer. Lancet. 359:2002;1341-1342.
2. Kramer B.S., Brown M.L., Prorok P.C., et al. Prostate cancer screening what we know and what we need to know. Ann Intern Med. 119:1993;914-923.
3. Schroder F.H., Boyle P. Screening for prostate cancer - necessity or nonsense? Eur J Cancer. 29A:1993;656-661.
4. Woolf S.H. Screening for prostate cancer with prostate-specific antigen an examination of the evidence. N Engl J Med. 333:1995;1401-1405.
5. Standaert B., Denis L. The European Randomized Study of Screening for Prostate Cancer an update. Cancer. 80:1997;1830-1834.
6. Kramer B.S., Gohagan J., Prorok P.C., et al. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cance. 71:(2 suppl):1993;589-593.
7. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:1993;948-954.
8. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 58:2001;417-424.
9. Lu-Yao G.L., Greenberg E.R. Changes in prostate cancer incidence and treatment in USA. Lancet. 343:1994;251-254.
10. Lu-Yao G, Albertsen PC, Stanford JL, et al: Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325: 740, 2002.
11. Majeed A., Babb P., Jones J., et al. Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int. 85:2000;1058-1062.
12. Oliver S.E., May M.T., Gunnell D. International trends in prostate-cancer mortality in the "PSA era" Int J Cancer. 92:2001;893-898.
13. Etzioni R, Legler JM, Feuer EJ, et al: Cancer surveillance series: interpreting trends in prostate cancer - part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91: 1033-1039, 1999.
14. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 38:1999;83-91.
15. Jacobsen S.J., Katusic S.K., Bergstralh E.J., et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 274:1995;1445-1449.
16. Potosky A.L., Miller B.A., Albertsen P.C., et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 273:1995;548-552.
17. Giovannucci E., Kantoff P., Spiegelman D., et al. The "epidemic" of early prostate cancer and the medical literature a causal association? Prostate Cancer and Related Diseases. 1:1998;148-153.
18. Dugan J.A., Bostwick D.G., Myers R.P., et al. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 275:1996;288-294.
19. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 94:2002;981-990.
20. Hugosson J., Aus G., Becker C., et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int. 85:2000;1078-1084.
21. McGregor M., Hanley J.A., Boivin J.F., et al. Screening for prostate cancer estimating the magnitude of overdetection. Can Med Assoc J. 159:1998;1368-1372.
22. Smith D.S., Carvalhal G.F., Mager D.E., et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol. 160:1998;1734-1738.
23. Eskew L.A., Bare R.L., McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 157:1997;199-202.
24. Fink K.G., Hutarew G., Lumper W., et al. Prostate cancer detection with two sets of ten-core compared with two sets of sextant biopsies. Urology. 58:2001;735-739.
25. Emiliozzi P., Longhi S., Scarpone P., et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol. 166:2001;845-850.